GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.
ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.
Our Paper about PIK3CA-Mutations is one of the most-cited papers in JCO.
Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.
Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd